Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
G1 Therapeutics Inc (GTHX)
NASDAQ:GTHX
Holding GTHX?
Track your performance easily
GTHX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.08 - $7.19
Previous Close$7.15
Volume1.27M
Average Volume (3M)2.29M
Market Cap
$377.22M
Enterprise Value$364.44M
Total Cash (Recent Filing)$60.73M
Total Debt (Recent Filing)$47.95M
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Oct 30, 2024EPS Estimate
-$0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.86
Shares Outstanding52,758,191
10 Day Avg. Volume1,712,563
30 Day Avg. Volume2,289,298
Standard Deviation0.31
R-Squared0.08
Alpha-0.00374
Financial Highlights & Ratios
Price to Book (P/B)15.21
Price to Sales (P/S)6.48
Price to Cash Flow (P/CF)-17.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.26
Enterprise Value/Gross Profit4.84
Enterprise Value/Ebitda-10.89
Forecast
1Y Price Target
$7.15Price Target Upside0.00%
Rating ConsensusHold
Number of Analyst Covering6
G1 Therapeutics News
PremiumCompany Announcements
Pharmacosmos Acquires G1 Therapeutics, Enhances Cancer Therapy Reach
Bulls Say, Bears Say
Bulls Say
AcquisitionPharmacosmos is acquiring G1 Therapeutics at a 68% premium, showcasing strong confidence in G1's potential.
Growth PotentialCosela generated $46M in sales last year and is projected to reach $60-70M, indicating significant growth prospects.
Product ApprovalCosela is the first and only FDA-approved product to reduce chemotherapy-induced myelosuppression in adult patients.
Bears Say
Clinical TrialsTopline results from PRESERVE 2 trial did not reach statistical significance for overall survival.
Drug DevelopmentTrilaciclib in combination with gemcitabine + carboplatin failed to demonstrate a significant OS benefit over GC alone.
Stock RatingDue to the announced acquisition of G1 by Pharmacosmos, the stock rating is being downgraded to Neutral.
---
Ownership Overview
27.31% Insiders
14.58% Mutual Funds
21.15% Other Institutional Investors
36.96% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GTHX FAQ
What was G1 Therapeutics Inc’s price range in the past 12 months?
G1 Therapeutics Inc lowest stock price was $1.08 and its highest was $7.19 in the past 12 months.
What is G1 Therapeutics Inc’s market cap?
Currently, no data Available
When is G1 Therapeutics Inc’s upcoming earnings report date?
G1 Therapeutics Inc’s upcoming earnings report date is Oct 30, 2024 which is 10 days ago.
How were G1 Therapeutics Inc’s earnings last quarter?
G1 Therapeutics Inc released its earnings results on Aug 08, 2024. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.165 by $0.065.
Is G1 Therapeutics Inc overvalued?
According to Wall Street analysts G1 Therapeutics Inc’s price is currently same.
Does G1 Therapeutics Inc pay dividends?
G1 Therapeutics Inc does not currently pay dividends.
What is G1 Therapeutics Inc’s EPS estimate?
G1 Therapeutics Inc’s EPS estimate is -$0.07.
How many shares outstanding does G1 Therapeutics Inc have?
G1 Therapeutics Inc has 37,582,000 shares outstanding.
What happened to G1 Therapeutics Inc’s price movement after its last earnings report?
G1 Therapeutics Inc reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.165. Following the earnings report the stock price went up 0.425%.
Which hedge fund is a major shareholder of G1 Therapeutics Inc?
Among the largest hedge funds holding G1 Therapeutics Inc’s share is Woodline Partners LP. It holds G1 Therapeutics Inc’s shares valued at 3M.
---
G1 Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$7.15 (0.00% )
$7.15 (0.00% )
Blogger Sentiment
Bullish
GTHX Sentiment 83%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $42.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
433.58%
12-Months-Change
Fundamentals
Return on Equity
-109.01%
Trailing 12-Months
Asset Growth
-33.27%
Trailing 12-Months
Company Description
G1 Therapeutics Inc
G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.
---
GTHX Earnings Call
Q1 2024
0:00 / 0:00
---
GTHX Stock 12 Month Forecast
Average Price Target
$7.15
▲(0.00% Upside)
Technical Analysis
TG Therapeutics
―
Mersana Therapeutics
―
Blueprint Medicines
―
Karyopharm Therapeutics
―
Best Analysts Covering GTHX
1 Year
1 Year Success Rate
1/6 ratings generated profit
1 Year Average Return
-20.05%
reiterated a buy rating 7 months ago
Copying Anthony Butler's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -20.05% per trade.
---